Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523789 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| Bromide SCHEMBL1179592 | 0.99 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| Bromide SCHEMBL1179587 | 0.99 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4743333 | 0.99 | LMNA (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1180205 | 0.95 | TACR1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1109929 | 0.95 | TACR1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1109925 | 0.95 | LMNA (0.32) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4741997 | 0.93 | CHRM1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4741995 | 0.93 | CHRM1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL435135 | 0.91 | CYP19A1 (0.37) | CHRM2CHRM1KCNH2LMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | claimed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | claimed |
| WO-2010008341-A1 | A COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A MUSCARINIC ANTAGONIST | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | claimed |
| EP-2124941-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | Argenta Discovery Limited (GB) | 2009-12-02 | — | — | EP | claimed |
| EP-2125728-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008103125-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | claimed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | claimed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | claimed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| EP-2624838-A1 | NOVEL COMBINATIONS | AstraZeneca AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046050-A1 | NOVEL COMBINATIONS | ASTRAZENECA AB (SE) | 2012-04-12 | — | — | WO | disclosed |
| EP-2414376-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A STEROIDAL[3,2-C]PYRAZOLE DERIVATIVE AND A SECOND PHARMACEUTICALLY ACTIVE COMPOUND | AstraZeneca AB (SE) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2124941-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | Argenta Discovery Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-2125728-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008103125-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | CHRM2 1106/4885CHRM1 1212/4885KCNH2 881/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | CHRM2 1149/4885CHRM1 1204/4885KCNH2 972/4885 |
| US-20110136843-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | CCR1, CCR5, CCR3 | CHRM2 34/4885CHRM1 44/4885KCNH2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.